See the published version of this preprint at BMC Endocrine Disorders.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Julius Chacha Mwita
University of Botswana
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5947-3684
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background There is evidence of statin benefit among patients with diabetes regardless of their cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods The study was a secondary data analysis of 374 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescription. Results Overall, 356 (95.2%) participants were eligible for a statin prescription. Clinicians prescribed statins in 162 (45.5%%; 95% confidence interval CI: 40.4% - 50.7%)) of eligible participants, and only one (5.5%) ineligible participant. The probability of statin prescription was high in participants with high baseline low-density lipoprotein cholesterol (risk ratio RR: 1.49; 95%CI: 1.17 - 1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00 - 1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06 - 1.74). Conclusion Most patients with type 2 diabetes are not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescription. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations.
Key words: statin, type 2 diabetes mellitus, prescription and Botswana
Keywords
statin, type 2 diabetes mellitus, prescription and Botswana
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Endocrine Disorders.
No community comments so far
Submission checks complete
On 26 Feb, 2020
Editorial decision: Accept
On 26 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 19 Feb, 2020
Review #3 received
Received 16 Jan, 2020
Reviewer #3 agreed
On 02 Jan, 2020
Review #2 received
Received 30 Dec, 2019
Reviewer #1 agreed
On 23 Dec, 2019
Reviewer #2 agreed
On 23 Dec, 2019
Review #1 received
Received 23 Dec, 2019
Editor assigned
On 22 Dec, 2019
Reviewers invited
Invitations sent on 22 Dec, 2019
Submission checks complete
On 21 Dec, 2019
Editor invited
On 21 Dec, 2019
Version 1
Posted 03 Jul, 2019
No comments provided
Editorial decision: Major revision
On 04 Dec, 2019
Review #3 received
Received 05 Nov, 2019
Review #2 received
Received 31 Oct, 2019
Reviewer #3 agreed
On 18 Oct, 2019
Reviewer #2 agreed
On 17 Oct, 2019
Review #1 received
Received 25 Jul, 2019
Reviewer #1 agreed
On 10 Jul, 2019
Reviewers invited
Invitations sent on 06 Jul, 2019
Submission checks complete
On 28 Jun, 2019
Editor invited
On 28 Jun, 2019
Editor assigned
On 26 Jun, 2019
First submitted
On 24 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Endocrine Disorders.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Julius Chacha Mwita
University of Botswana
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5947-3684
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Endocrine Disorders.
No community comments so far
Submission checks complete
On 26 Feb, 2020
Editorial decision: Accept
On 26 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 19 Feb, 2020
Review #3 received
Received 16 Jan, 2020
Reviewer #3 agreed
On 02 Jan, 2020
Review #2 received
Received 30 Dec, 2019
Reviewer #1 agreed
On 23 Dec, 2019
Reviewer #2 agreed
On 23 Dec, 2019
Review #1 received
Received 23 Dec, 2019
Editor assigned
On 22 Dec, 2019
Reviewers invited
Invitations sent on 22 Dec, 2019
Submission checks complete
On 21 Dec, 2019
Editor invited
On 21 Dec, 2019
Version 1
Posted 03 Jul, 2019
No comments provided
Editorial decision: Major revision
On 04 Dec, 2019
Review #3 received
Received 05 Nov, 2019
Review #2 received
Received 31 Oct, 2019
Reviewer #3 agreed
On 18 Oct, 2019
Reviewer #2 agreed
On 17 Oct, 2019
Review #1 received
Received 25 Jul, 2019
Reviewer #1 agreed
On 10 Jul, 2019
Reviewers invited
Invitations sent on 06 Jul, 2019
Submission checks complete
On 28 Jun, 2019
Editor invited
On 28 Jun, 2019
Editor assigned
On 26 Jun, 2019
First submitted
On 24 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Endocrine Disorders.
Background There is evidence of statin benefit among patients with diabetes regardless of their cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods The study was a secondary data analysis of 374 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescription. Results Overall, 356 (95.2%) participants were eligible for a statin prescription. Clinicians prescribed statins in 162 (45.5%%; 95% confidence interval CI: 40.4% - 50.7%)) of eligible participants, and only one (5.5%) ineligible participant. The probability of statin prescription was high in participants with high baseline low-density lipoprotein cholesterol (risk ratio RR: 1.49; 95%CI: 1.17 - 1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00 - 1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06 - 1.74). Conclusion Most patients with type 2 diabetes are not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescription. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations.
Key words: statin, type 2 diabetes mellitus, prescription and Botswana
Loading...